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Introduction
Mathematical modelling serves as a valuable tool for
understanding the growth and evolution of populations.
When populations of parasites are considered, such
models can yield insight into how diseases spread, how
pathogens evolve, and what control strategies and medical
interventions would be most effective at reducing parasite
prevalence and minimizing the chance of undesirable evo-
lutionary outcomes. An important example of such an
undesirable outcome is drug treatment driving the evolu-
tion of drug-resistant parasites, a process that in the long-
term can render entire classes of drugs ineffective against
a particular disease. Malaria parasites have evolved resis-
tance to all known antimalarial drugs except the artemis-
insins. Recently, however, even the artemisinin-class drugs
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Abstract
Understanding the evolution of drug resistance in malaria is a central area of
study at the intersection of evolution and medicine. Antimalarial drug resis-
tance is a major threat to malaria control and directly related to trends in
malaria attributable mortality. Artemisinin combination therapies (ACT) are
now recommended worldwide as ﬁrst line treatment for uncomplicated
malaria, and losing them to resistance would be a disaster for malaria control.
Understanding the emergence and spread of antimalarial drug resistance in the
context of different scenarios of antimalarial drug use is essential for the devel-
opment of strategies protecting ACTs. In this study, we review the basic mech-
anisms of resistance emergence and describe several simple equations that can
be used to estimate the probabilities of de novo resistance mutations at three
stages of the parasite life cycle: sporozoite, hepatic merozoite and asexual blood
stages; we discuss the factors that affect parasite survival in a single host in the
context of different levels of antimalarial drug use, immunity and parasitaemia.
We show that in the absence of drug effects, and despite very different parasite
numbers, the probability of resistance emerging at each stage is very low and
similar in all stages (for example per-infection probability of 10
)10–10
)9 if the
per-parasite chance of mutation is 10
)10 per asexual division). However, under
the selective pressure provided by antimalarial treatment and particularly in the
presence of hyperparasitaemia, the probability of resistance emerging in the
blood stage of the parasite can be approximately ﬁve orders of magnitude
higher than in the absence of drugs. Detailed models built upon these basic
methods should allow us to assess the relative probabilities of resistance emer-
gence in the different phases of the parasite life cycle.
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2008) showing prolonged parasite clearance times in
patients. This does not yet amount to full-blown resis-
tance and fortunately appears to be conﬁned to Western
Cambodia. However, the concern is that further evolution
of this resistant phenotype or the emergence of a novel
fully resistant phenotype and its subsequent spread may
render useless this last bastion of antimalarial treatment.
Sadly, there are currently no suitable alternative drugs
nearing the ﬁnal stages of development by pharmaceutical
companies.
Most mathematical models of drug resistance in
malaria have focused on the spread of resistance and
assumed that multiple copies of a resistance mutation
were already present in the parasite population (Cross
and Singer 1991; Levin 2002; Koella and Antia 2003;
Yeung et al. 2004). Examining spread is useful when resis-
tance has already arisen in an area, however, it is also
very important to look at the emergence of resistance to a
drug to which resistance has not yet appeared. This is
particularly pertinent for artemisinin-class drugs as these
are the only drugs that show no evidence of overt resis-
tance in vivo (Barnes and White 2005). Artemisinin-based
combination therapies (ACTs) are recommended world-
wide as ﬁrst-line treatment for Plasmodium falciparum
malaria because they are highly effective with almost no
side effects (Newton et al. 2003; Adjuik et al. 2004; Ashley
and White 2005; Dondorp et al. 2005; Hutagalung et al.
2006; Smithuis et al. 2006; World Health Organisation
2006). Combination therapies in general are used speciﬁ-
cally to prevent the emergence of resistance. If ACTs were
lost to resistance, global malaria control efforts would be
seriously harmed and signiﬁcant excess malaria morbidity
and mortality would occur.
The beneﬁt of combination therapy is twofold. First, if
two drugs with different modes of action are co-formu-
lated in a combination therapy, the parasite’s probability
of inheriting resistance mutations to both drugs is the
product of the probabilities of inheriting resistance muta-
tions to each drug (White and Pongtavornpinyo 2003);
this is usually a very small number. An exception to this
rule occurs when one resistance mechanism, such as an
efﬂux pump, confers resistance to many types of drugs
simultaneously. Second, if resistance requires two or more
genetic changes, the obligate sexual recombination that
occurs in the Plasmodium life cycle can break apart the
gene combination(s) required to encode resistance to
both components of the combination therapy, thus slow-
ing, or even preventing, the establishment and spread of
resistance (Curtis and Otoo 1986; Dye and Williams
1997; Hastings 1997).
If ACTs are to be deployed in an area where there is
no resistance to either combination of drugs or perhaps
some resistance to the partner drug, it would be helpful
to be able to predict the interval of time before artemisi-
nin resistance is likely to emerge given information on
entomological, epidemiological and pharmacological fac-
tors. Cost-effectiveness analysis based on these models
can be a powerful tool to inform national drug policy
decisions, in particular in helping to persuade people that
the higher initial cost of ACTs will eventually be offset by
its longer useful therapeutic life (Institute of Medicine,
2004; Yeung et al. 2004).
In this study, we extend previous methods (Hastings
2004; Pongtavornpinyo 2006) and look at this early stage
of resistance evolution, often referred to as resistance
emergence, and consider at which stage of the parasite life
cycle – mosquito, liver, or blood – this emergence is most
likely to occur. We present the basic evolutionary equa-
tions that can be used to assess the relative probabilities
of resistance emergence in these three stages. For very
accurate estimates, we would rely on dynamical models
detailing host immunity, pharmacokinetics, ﬁtness varia-
tion for different levels of resistance, and details on game-
tocyte switching rates.
Methods
We consider resistance emergence independently at each
stage of the parasitic life cycle. The probability of emer-
gence is the combined probabilities of two events: the
probability of any mutant occurring, and the probability
of that mutant surviving in the population of parasites in
a single host. Fixation of resistant phenotypes can occur
at the bottlenecks separating the stages of the parasites’
life cycle. The genetic bottleneck for sporozoites entering
a human host from a mosquito and for gametocytes in
the blood stage being sampled by a mosquito is very
small (the order of one to ten parasites), whereas the bot-
tleneck experienced by hepatic merozoites emerging from
the liver is less severe and highly dependent on the
amount of residual drug present in the bloodstream. Note
that drugs are only present in the bloodstream and thus
do not affect resistance emergence and evolution during
the mosquito stage or liver stage.
Sporozoites
It is estimated that approximately 6–10 sporozoites
(and on rare occasions, >100) are injected into a
human host during one mosquito bite. In this study, it
is assumed that an infection derives from a single spo-
rozoite, the other sporozoites being lost due to stochas-
tic effects or the actions of host immunity. Resistance
can emerge when a sporozoite spontaneously mutates
inside a mosquito, resulting in a resistant phenotype,
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bottleneck and the sole founder of the population of
parasites in the liver.
Let l represent the per-parasite probability that a
mutation will occur during parasite replication. The
same hypothetical resistance mutation is assumed in
each parasite stage (i.e. the value of l is constant
across different stages) and is proportional to the DNA
polymerase error rate during mitotic division. Let s be
the number of generations from the gametocyte stage
taken during blood meal to the sporozoites number in
the mosquito’s salivary gland (s   10).
Because we assume that a single sporozoite founds the
population of parasites in the liver, the probability that
this parasite mutated during s generations of replication
in the mosquito is:
ls ¼ 1  ð 1   lÞ
s: ð1Þ
This is also the probability that such a mutation occurs
and goes to ﬁxation, because a single parasite founds the
infection. Therefore,
Ps ¼ ls; ð2Þ
which is s · l when l is small; if we assume that l =1 0
)10
then, ls =1 0
)9 (Gatton et al. 2001; Paget-McNicol and
Saul 2001; White and Pongtavornpinyo 2003).
Hepatic merozoites
When hepatic (liver-stage) merozoites leave the liver the
newly invaded blood cells may be exposed to residual
drug levels from a patient’s previous treatment, and thus
might be sufﬁcient to kill either the entire parasite popu-
lation (including emerging resistant mutants) or just the
sensitive parasites (a patient would not be given drugs at
this stage of the infection as he or she would not yet be
ill). If a newly acquired infection emerges from the liver
during a particular drug’s selective window (Watkins and
Mosobo 1993; Stepniewska and White 2008), resistant
parasites will survive while sensitive parasites will con-
tinue to be eliminated.
Let h be the number of mitotic divisions required by a
single hepatic schizont (initial stage of liver infection) to
produce 10
5 parasites in the liver and to be released into
the blood. Note that h in this section is not the number
of generations of parasite replication (as was the parame-
ter s in the previous section). The parameter h is on the
order of 10
5–10
6, and
lh ¼ 1  ð 1   lÞ
h; ð3Þ
where l is again 10
)10; lh is between 10
)5 and 10
)4 and
represents the probability that a resistance mutation
occurs at some point during parasite replication in the
liver, in the absence of drugs.
The survival of the emerging resistant merozoites is
affected by any residual slowly eliminated drugs that are
present in the blood as the parasites leave the liver for the
bloodstream. Focusing on ACT treatment, we discuss the
emergence of artemisinin resistance in the presence of
residual artemisinin. In general, the residual drug factor
can be incorporated into population-genetic equations by
assuming two periods with different concentrations or
levels of drug. Initially, there is a high level of drug, a
concentration high enough to kill both resistant and sen-
sitive parasites. Subsequently, there is a low level, i.e. a
level that falls into the selective window killing sensitive
parasites but allowing the survival of resistant parasites.
When there is a low level of residual drugs, selection takes
place.
We consider the situation where there exists some
residual partner drug. Let c be the probability that the
emerged merozoites already have partner drug resistance.
Let a be the probability that the hepatic merozoites
encounter artemisinin drug levels in the artemisinin selec-
tive window (a low level of artemisinin). From a human
population perspective, a is equivalent to the proportion
of people with residual artemisinin within the selective
window. For artemisinins, a is usually zero or if it exists
is extremely small because the elimination half-life of the
artemisinin is only 1 h in comparison with the ‡48 h
asexual cycle of the malaria parasites (Stepniewska and
White 2008).
Let FAB be the probability of ﬁxation of the double-
resistant in the presence of both artemisinin and the part-
ner drug. In our scenario of complete resistance, FAB is
probably close to 1. The probability of artemisinin-resis-
tance emerging and ﬁxing from the hepatic merozoite
stage is
Ph ¼ c  ½ a   lh   FAB þð 1   aÞ lh   10 5 ; ð4Þ
where the 10
)5 term in the right-hand side represents
the probability of random ﬁxation in a population of
size 10
5. Note that (1)a) represents the probability that
there is abundant artemisinin or no artemisinin; in the
ﬁrst scenario, artemisinin kills all parasites so ﬁxation
probability is zero while in the second scenario artesu-
nate has equal killing rates for partner drug resistant and
sensitive parasites so ﬁxation probability is 10
)5. In equa-
tion (4), we therefore assume that the extremely short
half-life of artemisinin ensures that the frequency of sce-
nario 1 is negligible compared to scenario 2. We assume
that if there is no resistance to the partner drug, an arte-
misinin-resistant parasite would have a negligible chance
of surviving; this assumption can of course be relaxed.
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of being in the artemisinin selective window and a high
chance of pre-existing partner-drug resistance, is on the
order of 10
)7.I fa <1 0
)6, then the probability in equa-
tion (4) is dominated by random ﬁxation and is of the
order 10
)10.
In the absence of any residual drugs, there is no bottle-
neck and therefore the probability of resistance emerging
is just the probability that a resistance mutation occurs at
some point and then goes to ﬁxation (for this example,
the probability of this event would be 10
)10).
Blood-stage parasites
Here, we consider emergence of resistant parasites during
blood-stage infection, assuming that these parasites did
not encounter residual drug when entering the blood-
stream from the liver. The parasites may encounter drugs
at this stage if their population size crosses the pyrogenic
threshold (10
8) causing the patient to be ill and to be
treated with an ACT. We do not consider the case of
presumptive treatment for a nonmalarial fever or inter-
mittent presumptive treatment given to infants or preg-
nant women. In order to be transmitted to a mosquito
feeding on a host, malaria parasites need to develop into
gametocytes; gamotocytaemia in P. falciparum infections
is delayed with respect to blood-stage parasitaemia. In
this stage of the infection, we calculate the probability
(Pb) that resistance emerges and the probability that
resistant gametocytes are produced and sampled by a
mosquito during a blood meal. Mosquito sampling can
be viewed as the ﬁxation event in the blood stage of the
infection, and the bottleneck here is again quite small. Pb
is calculated after 10 cycles of blood-stage replication
( 20 days)
The emergence of resistance in blood-stage parasites
occurs when the genetic changes (mutation or gene dupli-
cation) which confer antimalarial drug resistance occur
spontaneously and independently of antimalarial drugs.
Hereafter, we use the term mutation to include any
genetic change conferring resistance. For resistance to
spread the resistant, mutant parasites must survive both
antimalarial drug effects and host-defence mechanisms. A
simple model of de novo resistance in the blood-stage
infection was developed (see Supporting Information)
which describes the stages of reproduction in the blood
after hepatic merozoites are released from the liver and
multiply to a density which can start gametocyte produc-
tion (see Fig. 1). For the ﬁrst cycle, the probability of
mutation occurring among the hepatic merozoites invad-
ing the red blood cell ( 10
5) is calculated. For all other
cycles, the probability of mutation occurring among the
blood-stage parasites in each cycle is calculated. Once
mutation occurs, both the sensitive and resistant parasites
would multiply over the succeeding cycles, depending on
the multiplication factor (m). The parasite multiplication
rate every 48 h in the asexual life cycle is determined
mainly by the efﬁciency of merogony or merozoite inva-
sion (White et al. 1992); in our model, it is also affected
by antimalarial drugs and host immunity. We assume
that the effect of treatment on killing parasites, the effect
of host immunity on suppressing parasites and the multi-
plication of the parasites are acting simultaneously in a
single cycle. The bottleneck at the blood stage is identiﬁed
as the chance of transmitting resistance through to the
sexual stages.
We deﬁne lt as the probability that a mutant emerges
from blood stage at cycle t when the population size is pt.
In each cycle, the probability of exactly one mutant
occurring in cycle t is
lt ¼ pt   l  ð 1   lÞ
pt 1; ð5Þ
which is about pt · l if we assume that l
2 is small. For
the blood stage, we again assume that at most one resis-
tant mutant can emerge.
The probability of resistance ﬁrst emerging at cycle t is
et ¼ð 1   l1Þ ð 1   l2Þ ...ð1   lt 1Þ lt: ð6Þ
We consider the possibility of switching to gametocytes
for cycles t =1t ot = 10. It is assumed that the resistant
and sensitive parasites have equal chances of switching to
gametocytes, independently of antimalarial treatment but
dependent upon the parasite density. Although previous
studies have shown that parasites can facultatively alter
investment in gametocyte production in response to
drugs (Buckling et al. 1997) and many other risk factors
for gametocyte carriage (Price et al. 1999), we do not
include such complications and only model a binary
switching rate.
Letting r10,k and p10,k be the numbers of resistant and
total parasites, respectively, at cycle 10 given that a
mutant parasite emerged ﬁrst at cycle k, we can calculate
these numbers for any cycle k and condition on the cycle
that resistance ﬁrst appears. For example, if an artemisi-
nin-resistant mutant parasite emerges ﬁrst at cycle 10, the
probability that one of these mutants develops into a
gametocyte and is transmitted is
r10;10=p10;10: ð7Þ
The numbers of resistant (rt) and sensitive (st) parasites
are calculated in a standard discrete-generation popula-
tion-genetic framework where rt depends on rt)1, st
depends on st)1, and pt = rt + st, as described in the Sup-
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occurring during the blood stage and surviving to trans-
mit is just the sum of the probabilities of resistance
emerging in any cycle, multiplied by the chance of those
resistant progeny switching to gametocytes and infecting
a mosquito; we write this as
Pb ¼
X 10
t¼1
et   r10;t=p10;t: ð8Þ
The details of the dynamic model are given in
Appendix B. As an example, when l =1 0
)10 and the
parasite multiplication rate m = 10, the chance of
resistance emerging in a nonimmune person from a low-
transmission setting without treatment effect (Pb)i s
5.39 · 10
)10.
Alternatively, we derive a simple calculation of the
probability of resistance emerging at the blood stage by
looking at the time of treatment. Let b be the number of
cycles required for the parasites to multiply in number
from the ﬁrst cycle to the parasite level (v) where treat-
ment is given (b   6). The probability that any single
parasite (after b cycles of reproduction) contains a resis-
tance mutation is
lb ¼ 1  ð 1   lÞ
b ð9Þ
so that an infection with v parasites has a probability
v · lb (providing v · lb << 1) of containing a
spontaneous resistance mutation. Let s be the chance of
an infection being treated and qR be the chance of a resis-
tant parasite surviving treatment, the host-immune
response and reaching the density that gametocytes are
sufﬁciently produced for transmission. Then, the proba-
bility that a given infection of biomass v contains a resis-
tant mutation that survives in the blood stage is
Pb ¼ v   lb   s   qR ¼ v  ½ 1  ð 1   lÞ
b  s   qR:
ð10Þ
Further details are given in Appendix C. In the Results
section, we focus on blood-stage emergence using the
dynamic model only.
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rt = no. of resistant parasites at cycle t 
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1 − µ2
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 =  (1 − µ1)·(1 − µ2)·
     (1 − µ3)...(1-µ(n−1))·µn
µ3
µt = probability of resistance emerging at cycle t
1 − µ3
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Figure 1 The various stages at which resistance can emerge during the blood stage. The model is implemented in Microsoft Excel.
Drug resistance in malaria’s life cycle Pongtavornpinyo et al.
ª 2009 The Authors
56 Journal compilation ª 2009 Blackwell Publishing Ltd 2 (2009) 52–61Results
To calculate the probability of resistance emerging in the
sporozoite and hepatic merozoite stages, we used equa-
tions (2) and (4) while a dynamic model (available in the
on-line Supporting Information; see Fig. 1) was used to
calculate the resistance emergence probability at the asex-
ual blood stage (equation 8). Several particular situations
of resistance emergence, in addition to the basic scenarios
outlined in the methods, merit closer attention.
Consider the example of two extreme transmission
intensity settings. In a low-transmission setting, treatment
becomes important as infected hosts have little immunity
and are therefore more likely to experience malaria symp-
toms and seek treatment. The effects of antimalarials and
host immunity on the emergence of resistance occur
mainly in the blood stage. In a high-transmission setting,
immunity reduces the likelihood of symptoms but many
people will receive presumptive antimalarials whenever
they experience febrile symptoms due to other causes.
This occurs because fevers in such areas are assumed to
be due to malaria and most people in high-transmission
settings carry malaria parasites. In this case, the chance of
resistance emerging from the mutant merozoite seeing
residual drug level when released from the liver is much
greater, although the numbers of parasites exposed to
residual levels and their individual survival probabilities
are much lower.
To explore resistance emergence in the blood stage, the
baseline scenario is deﬁned as the case where treatment is
absent. Figure 2 shows the parasite biomass in the
absence of treatment for the low- and high-transmission
setting. The parameter estimates for these scenarios, given
in Appendix D, are set such that the parasite-time curves
are similar to what could be observed in the ﬁeld. In
the baseline scenarios, the main difference between the
high-transmission and low-transmission scenarios is the
presence of host immunity. The effect of immunity incor-
porated into this model acts mainly to reduce the parasite
multiplication rate. The reduction in multiplication rate
leads to a slow increase or even a decrease in the parasite
population, equally for sensitive and resistant parasites.
This results in a smaller chance of mutant parasites devel-
oping into gametocytes and passing through the transmis-
sion bottleneck. In the low-transmission setting, the
chance of resistance emerging in the blood stage in the
absence of treatment (Pb) is estimated to 5.39 · 10
)10
(Fig. 3). In the high-transmission setting, immunity sup-
presses the level of parasites below 10
8 preventing any
emerged resistance from being transmitted through
gametocytes.
An additional effect of immunity is that it decreases a
patient’s chance of becoming symptomatic (i.e. there is a
greater per-infection probability of infection resolution
below the density threshold at which illness develops). In
low-transmission settings where there is less immunity,
hosts present with symptoms more often. In general, the
effect of this on the risk of resistance emergence resistance
is difﬁcult to predict [but see Figure 3 of Boni et al.
(2008b)]. For model comparison, and simplicity, the
pyrogenic threshold (py) or the parasite density at which
the infection becomes symptomatic is assumed to be the
same for all infections.
The impact of deployment of ACT on the emergence
of arteminsinin resistance is considered with two possible
scenarios: (i) when parasites are sensitive to the artemisi-
nin’s partner drug and (ii) there is already resistance to
the artemisinin’s partner drug. If there is still no resis-
tance to the partner drug, it is assumed that ACTs kill
parasites effectively and this results in a 99.999% reduc-
tion in the artemisinin-sensitive parasite population and a
99.9% reduction in the artemisinin-resistant parasite pop-
ulation (as the partner drug is still efﬁcacious). In reality,
the treatment efﬁcacy could be smaller due to poor
adherence. If the partner drug is failing because of pre-
existing resistance, then the antimalarial effect is more
dependent on the artemisinin. To illustrate this, we
assume that in this case, the ACT can still kill 40% of the
parasites if the parasites are resistant to both artemisinin
and the partner drug. If the parasites are artemisinin-
sensitive but partner-drug resistant then the ACT is
assumed to kill 80% of the parasite population.
From Fig. 3, we conclude that artemisinin resistance is
most likely to emerge in an individual from a low-trans-
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Figure 2 The baseline scenarios for the low (black) and high (red)
transmission intensity setting respectively. In the absence of treatment,
the parasite biomass of a nonimmune person would increase lethally
over time. For a host with some immunity, the parasite biomass could
be suppressed around the detectable or pyrogenic levels. Parameter
estimates are given in Appendix D.
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with a partner drug to which resistance already exists
(Pb = 9.71 · 10
)7). An ineffective partner drug (due to
pre-existing resistance) not only reduces the efﬁcacy of
the ACT treatment, but also increases the chance of arte-
misinin-resistance emerging. In the high-transmission set-
ting, both speciﬁc and nonspeciﬁc immunity act to
reduce the parasite population, decreasing the chance of
resistance emerging and producing resistant gametocytes.
The chance of resistance emergence is relatively small in
high-transmission settings and situations when the part-
ner drug is still working.
As mentioned earlier, residual partner drug effects on
the emergence of resistance are more likely in high trans-
mission settings where presumptive drug use is common
(Hastings and Watkins 2005). When there are some resid-
ual drugs, we estimate the chance of resistance emerging
from the mutant merozoites leaving the liver (Ph) in the
range of 10
)10–10
)7 (equation 4). To prevent such an
event, it is important to minimize the chance of parasites
seeing residual drug level that fall in the selective window
by choosing appropriate combinations to which no resis-
tance exists and/or combinations whose elimination half-
lives are matched. In addition, the presumptive use of
some long elimination half-life antimalarials should also
be restricted.
The effect of hyperparasitaemia on the emergence of
resistance was also explored. Hyperparasitaemia is deﬁned
here as an infection in which the proportion of infected
erythrocytes varies from 5% to 70%. This is most likely
to result from unrestricted multiplication. We also mod-
elled two possible alternative causes: (i) a large number of
parasites released from the liver or (ii) more rapid
increase of parasites over the erythrocytic cycles (high
multiplication rate). These two parameters were modiﬁed
simultaneously to characterize the hyperparasitaemia
infection in the low-transmission setting: the parasite
multiplication rate and the initial number of hepatic mer-
ozoites. Hyperparasitaemia in the blood-stage model is
established through either an increase in the per-genera-
tion multiplication rate from 10 to 13 or an increase in
the initial number of parasites entering the blood stage
from 10
5 to 10
7.
Figure 3 shows the effect of hyperparasitaemia on the
probability of resistance emerging when the resistance to
the partner drug is present (Pb = 4.84 · 10
)6). Resistance
is more likely to emerge from hyperparasitaemic infec-
tions when treating with an ineffective ACT. The proba-
bility of resistance emergence increases more under the
hyperparasitaemic scenario where 10
7 parasites enter the
blood from the liver. When hyperparasitaemia is created
by an increase in the parasite multiplication rate, the
probability of resistance emergence does not differ from
nonhyperparasitaemia (Pb = 9.60 · 10
)7) as increasing
the multiplication rate causes an increase in both the sen-
sitive and resistant parasites equally.
Discussion
We investigated the origins of antimalarial resistance by
considering the likelihood of resistance emergence at
three different stages of the parasite life cycle: the sporo-
zoite stage, the hepatic merozoite stage and the asexual
blood stage. We concentrated particularly on artemisinin
resistance in the context of current use. Our estimates of
absolute probabilities of resistance emergence are not evi-
dence-based and may well be inaccurate. They make a
number of simplifying assumptions which may not be
1.E–10
1.E–09
1.E–08
1.E–07
1.E–06
1.E–05
1.E–04
1.E–03
1.E–02
P (resistance emerging)
P
s
P
b –non-immune or 
hyperparasitaemia
defined by multiplication
+ partner drug resistant
P
b –hyperparasitaemia
defined by initial parasite 
number + partner drug 
resistant
P
b –non-immune 
+ no treatment
Source of resistance emergence
P
h –in the absence 
of residual drugs
P
h –in the presence
of residual drugs 
Figure 3 The probability of artemisinin-resistance emerging at different stages. The dots show the probability of resistance emerging from the
sporozoite (Ps), the hepatic merozoite (Ph) and blood stage (Pb). The dotted line represents the range for the probability of resistance emerging in
the hepatic merozoite stage (Ph) in the presence of some residual drugs. For the blood stage, the probability of resistance emerging is calculated
at cycle 10 when total parasite biomass is equal or above 10
8.
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probabilities at different stages of the parasite life cycle.
This comparative analysis of the de novo resistance in
different stages of life cycle shows that in the absence of
antimalarials, the emergence of resistance is rare and
similar among the different stages of infection (estimated
range between 10
)10 < P <1 0
)9). Although parasite
numbers vary hugely among the different stages of
development, there is a series of bottlenecks which
tend to dominate the overall dynamics and evolution.
Exposure of the asexual cycle to antimalarial drugs, and
subsequent recrudescence allows selection of the resistant
subpopulation. Thus, in the speciﬁc case of artemisinin
combination treatment, artemisinin resistance is most
likely to emerge at the blood stage when there is already
resistance to the partner drug (10
)6 < Pb <1 0
)5) or when
liver-stage parasites ﬁrst enter the blood in small numbers
and encounter residual drug levels (10
)10 < Ph <1 0
)7).
The chance of resistance emergence increases in hyper-
parasitaemic infections (Pb =1 0
)5). Hyperparasitaemia
reﬂects a failure of host defence, and carries a greater risk
of recrudescence with concomitant gametocytaemia. This
is the essential ampliﬁcation step that leads to spread
(White and Pongtavornpinyo 2003). When we compared
different transmission intensity settings, the emergence of
resistance was more likely to occur from the blood stage
in a low-transmission area where the human population
is mostly nonimmunes and therefore treated. The chance
of resistance emerging from mutation at the hepatic mer-
ozoite stage is much lower for several reasons (Step-
niewska and White 2008) but could contribute if the
hosts are frequently exposed to antimalarials and tend to
have residual drug in their blood.
Understanding the driving force of resistance is neces-
sary when choosing an appropriate treatment strategy. If
resistance is driven by treatment failure, i.e. by the selec-
tion of mutant parasites in the blood stage at the time of
drug treatment, effective ACTs (in combination with a
still-effective partner drug) are beneﬁcial for delaying the
emergence of artemisinin resistance. However, if resis-
tance is driven by the selection of resistant mutant hepa-
tic merozoites encountering a subtherapeutic drug
concentration then the control of presumptive treatments
and the choice of combination therapies become more
important.
A possible solution to the problem of increasing anti-
malarial resistance, is to use a combination of three drugs
with one being an artemisinin derivative and the two
other drugs having longer, matching half-lives, but differ-
ent mechanisms of action, thereby protecting each other
after the rapid elimination of the artemisinin derivative.
This could be beneﬁcial in both delaying the emergence
and spread of resistance. The use of triple combination
drugs is not new: it is routinely used to treat other infec-
tious diseases such as HIV and tuberculosis.
It is important to mention some caveats and limita-
tions to the equations presented in this study. Like all
models, the one presented here has its limitations as it
does not take into account many important features
of malaria biology such as characteristics of the host-
immune response, var gene switching rates, gameto-
cytocidal effects of ACTs, complex variations in parasite
population size, different gametocyte switching rates for
resistant and sensitive parasites (Buckling et al. 1997),
patient adherence to drug regimen, mechanisms of
resistance and cross-resistance, factors affecting cure rates,
ﬁtness costs of resistance for resistant phenotypes and
many more.
In particular, the conclusion concerning resistance
emergence during the blood stage depends entirely on
how we quantify the various impediments that restrict
successful transmission of resistant forms from the treated
blood stage. These impediments (such as var switching,
low survival probabilities) appear substantial to explain
the genetic ﬁeld data that resistance to chloroquine and
sulphadoxine–pyrimthamine arises rarely (Hastings 2004).
They are formally present as qR in equation 10 but are
absent from the dynamic model equation 8 used to pro-
duce Fig. 3. Setting qR to a low value in equation 10
shows that these impediments can potentially make trea-
ted blood stages an unlikely source of mutation.
The assumption that a single point mutation was sufﬁ-
cient for the parasite to become resistant to the treatment
may raise some concerns. Some resistance arises from a
single point mutation (e.g. atovaquone resistance), but
other types of resistance arise through a series of muta-
tions or a primary mutation that provides an essential
step, augmented by secondary mutations that progres-
sively increase the level of resistance. A more comprehen-
sive model involving more complex genetic events may be
required (Sibley et al. 2001; Hastings et al. 2002a,b; Hyde
2002). When multiple unlinked events are required for
encoding resistance and when more than one parasite
genotype is considered, there is the possibility of out-
breeding of multigenic resistance mechanisms through
recombination breakdown during meiosis.
While more complex models will no doubt shed light
on the quantitative details of resistance emergence, sim-
pler models provide insights into the basic evolutionary
principles at work as the parasite moves through the dif-
ferent stages of its life cycle (Boni et al. 2008a). The sim-
ple model presented here gives some clues as to the
origins of antimalarial resistance, suggesting that blood-
stage replication and small parasite populations encoun-
tering residual drug are the most likely scenarios for the
emergence of drug resistance. This type of understanding
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and hopefully, design treatments that minimize the prob-
ability of resistance emerging. The dynamics of antimalar-
ial treatment and resistance evolution bring together the
most basic elements in the ﬁelds of medicine and evolu-
tion: treatment of a diseased patient with an effective
drug and the adaptation of an organism to a novel,
unfriendly environment. Knowledge from each ﬁeld sheds
light on the other and will hopefully lead to new develop-
ments that improve the long-term efﬁcacy of antimalarial
drugs and help relieve the overall human burden of
malaria.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Appendix S1. Additional assumptions. All model
assumptions based on all three stages where resistance
emerges are shown below.
Appendix S2. Details of the dynamic model for calcu-
lating the probability of resistance emergence in the blood
stage. The model is implemented in the Microsoft Excel
ﬁle given in the online supporting material.
Appendix S3. Calculation of the probability of resis-
tance emerging at the blood stage when the parasite is at
equilibrium.
Appendix S4. The parameter estimates for baseline sce-
narios when deriving the probability of resistance emerges
in the blood stage
Please note: Wiley-Blackwell are not responsible for the
content or functionality of any supporting materials sup-
plied by the authors. Any queries (other than missing
material) should be directed to the corresponding author
for the article.
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